Jasmin, Luzminda V.

HRN: 24-61-12  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/11/2024
CEFUROXIME 1.5GM (VIAL)
02/11/2024
02/17/2024
IVT
1.5g
Q8
T/C Osteosarcoma
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bone & JointSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: